To amend the Federal Food, Drug, and Cosmetic Act to prevent the use of patents, trade secrets, or other intellectual property to inhibit competition.
The bill’s titles are written by its sponsor.
Sponsor and status
118th Congress (2023–2025)
Introduced on Jul 17, 2023
This bill is in the first stage of the legislative process. It was introduced into Congress on July 17, 2023. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
Other activity may have occurred on another bill with identical or similar provisions.
History
|
Jul 17, 2023
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
|
|
If this bill has further action, the following steps may occur next: | |
|
—
|
|
Passed Committee
|
|
—
|
|
Passed House
|
|
—
|
|
Passed Senate
|
|
—
|
|
Signed by the President
|
H.R. 4692 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 4692. This is the one from the 118th Congress.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 4692 — 118th Congress: Increasing Prescription Drug Competition Act.” www.GovTrack.us. 2023. September 22, 2023 <https://www.govtrack.us/congress/bills/118/hr4692>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
